Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

EPRX

Eupraxia Pharmaceuticals (EPRX)

Eupraxia Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:TSX:EPRX
DateTimeSourceHeadlineSymbolCompany
07/03/20245:00PMPR Newswire (Canada)Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024TSX:EPRXEupraxia Pharmaceuticals Inc
07/03/20245:00PMPR Newswire (US)Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024TSX:EPRXEupraxia Pharmaceuticals Inc
06/06/20245:00PMPR Newswire (US)Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of ShareholdersTSX:EPRXEupraxia Pharmaceuticals Inc
06/06/20245:00PMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of ShareholdersTSX:EPRXEupraxia Pharmaceuticals Inc
06/05/20247:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024TSX:EPRXEupraxia Pharmaceuticals Inc
06/05/20247:00AMPR Newswire (US)Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024TSX:EPRXEupraxia Pharmaceuticals Inc
05/23/20245:00PMPR Newswire (US)Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
05/23/20245:00PMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
05/22/20247:00AMPR Newswire (US)Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024TSX:EPRXEupraxia Pharmaceuticals Inc
05/22/20247:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024TSX:EPRXEupraxia Pharmaceuticals Inc
05/21/20245:00PMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
05/21/20245:00PMPR Newswire (US)Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
05/14/20247:00AMPR Newswire (US)Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024TSX:EPRXEupraxia Pharmaceuticals Inc
05/14/20247:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024TSX:EPRXEupraxia Pharmaceuticals Inc
05/08/20245:03PMPR Newswire (US)Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateTSX:EPRXEupraxia Pharmaceuticals Inc
05/08/20245:03PMPR Newswire (Canada)Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateTSX:EPRXEupraxia Pharmaceuticals Inc
05/02/20247:00AMPR Newswire (US)Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory BoardTSX:EPRXEupraxia Pharmaceuticals Inc
05/02/20247:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory BoardTSX:EPRXEupraxia Pharmaceuticals Inc
04/11/20247:00AMPR Newswire (US)Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024TSX:EPRXEupraxia Pharmaceuticals Inc
04/11/20247:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024TSX:EPRXEupraxia Pharmaceuticals Inc
04/08/20247:00AMPR Newswire (US)Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor ConferenceTSX:EPRXEupraxia Pharmaceuticals Inc
04/08/20247:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor ConferenceTSX:EPRXEupraxia Pharmaceuticals Inc
04/05/20247:00AMPR Newswire (US)Eupraxia Pharmaceuticals Begins Trading on Nasdaq TodayTSX:EPRXEupraxia Pharmaceuticals Inc
04/05/20247:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Begins Trading on Nasdaq TodayTSX:EPRXEupraxia Pharmaceuticals Inc
04/03/20245:00PMPR Newswire (Canada)Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024TSX:EPRXEupraxia Pharmaceuticals Inc
04/03/20245:00PMPR Newswire (US)Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024TSX:EPRXEupraxia Pharmaceuticals Inc
04/01/20245:01PMPR Newswire (US)Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
04/01/20245:01PMPR Newswire (Canada)Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
03/12/20249:41AMPR Newswire (Canada)L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
03/12/20249:39AMPR Newswire (Canada)Canadian Investment Regulatory Organization Trade Resumption - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
 Showing the most relevant articles for your search:TSX:EPRX